NEW YORK, Nov. 11, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Biogen Inc. (“Biogen”) (NASDAQ:BIIB) between July 23, 2014 and July 23, 2015. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. To get more information go to:
http://www.zlk.com/pslra/biogen-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that the defendants employed devices, schemes and artifices to defraud, while in possession of material adverse non-public information, in an effort to assure investors of Biogen’s value and performance and continued substantial growth. In particular, the complaint alleges that the Company failed to disclose material information about the Company’s business, particularly in regards to their Tecfidera drug treatment.
In 2014, the MS Institute at Shepherd Center in Georgia, a prescriber of Tecfidera, began conducting blood tests of MS patients taking the drug. By August of that year, the Center began notifying Biogen that Tecfidera was causing low lymphocyte counts among approximately 30% of the Center’s MS patients taking the drug; eventually the Center stopped prescribing Tecfidera and transferred many of its patients to other therapies. Biogen, however, continued to tout the safety and growing sales of Tecfidera throughout the second and third quarter of 2014.
If you suffered a loss in Biogen you have until December 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 



